Biomind Labs, Inc. is a biotech research and development company focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND02 ? N, N-dimethytryptamine that is in Phase II clinical trials for use in the treatment of depression; and BMND01 ? Ayahuasca, a product candidate in pre-clinical trials for use in the treatment of smoking addiction. Its product candidates in evaluation stage include BMND03 ? Psilocybin for treating chronic pain; BMND04 ? Mescaline for treating eating disorders and neurodegenerative diseases; and BMND05 ? 5-MeO-DMT, an anti-inflammatory product. The company was founded in 2021 and is headquartered in Toronto, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company